NASDAQ$BCYC
Bicycle Therapeutics plc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported third quarter financial results and provided a corporate update.
Bicycle Therapeutics reported continued clinical progress across its pipeline and a strong balance sheet, supported by a $10 million option fee from Genentech. The company expects its financial runway to extend into 2025.
- Continued clinical progress across pipeline including BT5528 end of Phase I dose escalation update.
- Completion of enrollment in BT5528 initial dose expansion cohorts expected in Q4.
- BT8009 clinical update remains on-track for Q4.
- Received $10 million option fee payment from Genentech this quarter.
Headline financials
Revenue & EPS history
Bicycle · Revenue · Quarterly
$3.04M
Forward guidance
Bicycle Therapeutics anticipates continued advancement of its product candidates, dosing in and progression of its clinical trials, and expansion of its discovery efforts and early development pipeline, with an expected financial runway into 2025.
Tailwinds
- Advancement of product candidates BT5528, BT8009 and BT7480
- Dosing in and progression of clinical trials
- Availability and timing of announcement of data from clinical trials
- Therapeutic potential for Bicycles in oncology and other applications
- Plans to expand discovery efforts and early development pipeline
Headwinds
- Risks to clinical trial site initiation, patient enrollment and follow-up due to the ongoing COVID-19 pandemic
- Uncertainties inherent in the initiation and completion of clinical trials and clinical development of product candidates
- Risk that Bicycle may not realize the intended benefits of its technology
- Risk that projections regarding expected financial runway are inaccurate or that conduct of business requires more cash than anticipated
- Potential adverse effects arising from the testing or use of product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+19.3%
Q4 2019
Best reaction
-10.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +3.6% | -0.8% | |
| Q4 2025 | -4.2% | -13.9% | +1.8% | |
| Q3 2025 | +6.7% | -16.0% | -8.6% | |
| Q1 2025 | +6.1% | -13.6% | -4.0% | |
| Q4 2024 | -1.3% | -2.5% | -18.3% | |
| Q3 2024 | -5.5% | -2.2% | -15.1% | |
| Q2 2024 | -0.7% | +2.1% | -10.0% | |
| Q1 2024 | +1.6% | -4.6% | -8.3% | |
| Q4 2023 | +3.1% | +9.5% | +14.9% | |
| Q3 2023 | +1.2% | -0.7% | -2.3% | |
| Q2 2023 | +1.3% | -2.8% | -4.1% | |
| Q1 2023 | -0.4% | +2.5% | +15.7% | |
| Q4 2022 | -1.9% | -5.5% | -6.2% | |
| Q3 2022 | -3.2% | +0.8% | +29.6% | |
| Q2 2022 | +14.8% | +17.7% | +12.8% | |
| Q1 2022 | -10.8% | -22.6% | -33.6% | |
| Q4 2021 | -1.2% | -9.7% | -7.6% | |
| Q3 2021 | +0.7% | +2.5% | -6.8% | |
| Q2 2021 | +1.8% | +2.3% | +36.0% | |
| Q1 2021 | +1.9% | -1.3% | -5.5% | |
| Q4 2020 | +1.9% | +2.0% | +3.8% | |
| Q3 2020 | -1.5% | +3.1% | +5.2% | |
| Q2 2020 | -0.2% | +0.0% | +5.8% | |
| Q1 2020 | +0.7% | +6.6% | +23.2% | |
| Q4 2019 | +19.3% | +1.5% | -2.3% | |
| Q3 2019 | -4.2% | -7.7% | -4.8% | |
| Q2 2019 | +5.9% | +5.4% | -6.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro